Valirx (VAL)

 

VAL Share PerformanceMore

52 week high29.8000 06/10/15
52 week low5.7500 02/09/16
52 week change -15.2500 (-64.89%)
4 week volume34,752,783 03/09/16

Media for (VAL)

Presenter: Oliver de Giorgio-Miller
27/09/2016
Presenter: Dr George Morris
13/09/2016

Latest NewsMore

Notice of GM

RNS Number: 0779L ValiRx PLC 28 September 2016 VALIRX PLC ("ValiRx" or "the Company") SHAREHOLDERCIRCULAR AND NOTICE OF GENERAL MEETING London,UK, 28 September 2016:ValiRxPlc (AIM: VAL), a life science company which focuses on clinical stage cancertherapeutic development, taking proprietary& novel technology forprecision ...

Half-year Report

RNS Number: 8701K ValiRx PLC 27 September 2016 VALIRX PLC ("ValiRx", "the Company" or "the Group") HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2016 London, UK., 27 September 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technolog...

ValiRx - Half-year Report

ValiRx selected for The Parliamentary Review 2016

RNS Number: 7460K ValiRx PLC 26 September 2016 VALIRX PLC ("ValiRx", "the Company" or "the Group") ValiRx has been selected to appear in the 2015/16 edition of The Parliamentary Review "The Company features alongside The Chancellor of the Exchequer, The Rt Hon Philip Hammond, and a small number of outstanding organisations in the Technology...

Quarterly Update on Clinical Developments

RNS Number: 6226J ValiRx PLC 13 September 2016 Va li R x P lc ("ValiRx" or "the Company") QUARTERLY UPDATEON CLINICAL DEVELOPMENTS London, UK ., 13 September 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines...

ValiRx - Quarterly update on clinical developments

Valirx Plc to present at the SHARES Investor Evening in Edinburgh on 5th October 2016

Dr. George Morris, Chief Operations Officer of Valirx (VAL) (LSE:VAL) will be giving a briefing at the SHARES Investo...

Placing, issue of warrants & Convertible Loan

RNS Number: 8528I ValiRx PLC 02 September 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Placing, issue of warrants and Convertible Loan Facility London, UK ., 02 September 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision...

Fundamental DataMore

EPS-6.66
Dividend yield0 %

Equity Research (VAL)

edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

  • Interesting

    To see very high volume in early trading together with a firm SP -so let's hope this is backed up by tangible news in the very near future which supports our SP & enables ...
    29-Sep-2016
    dave297
  • Re: Thanks to those on LSE board

    So, mol, you can't rule out that 201 will deliver efficacy effects, based on this preliminary "look-see".
    28-Sep-2016
    Divmad
  • CT and val401

    updated here btw 130916 (don't think link posted here recently) for those who don't follow other boards (on occasion i can understand why - lol) i have noted sar recent ...
    28-Sep-2016
    mol42

Users' HoldingsMore

Users who hold Valirx also hold..
SOUND ENERGY17%
SAREUM17%
ROCKHOPPER16%
LLOYDS GRP.16%
RANGE RES.15%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL